Vice President, Development Sciences (Clinical Pharmacology & Nonclinical)

Lycia Therapeutics (Nasdaq: LYCA) is a clinical-stage biotechnology company using its proprietary lysosomal targeting chimera (LYTAC) platform to discover and develop therapeutics that degrade extracellular and membrane-bound proteins. These proteins drive a wide range of difficult-to-treat diseases, including autoimmune, inflammatory, and allergic conditions. Lycia was established in 2019 in collaboration with academic founder and Nobel Laureate Carolyn Bertozzi, Ph.D., professor of chemistry and HHMI investigator at Stanford University. In October 2026, Lycia completed an initial public offering, and its common stock now trades on the Nasdaq Global Select Market under the ticker symbol “LYCA.” Lycia is headquartered in South San Francisco. Visit https://lyciatx.com/ for more information. Position Summary Highly motivated, creative scientific leader to advance our pipeline of LYTAC degraders and help establish Lycia as the industry leader in endosomal-lysosomal degradation and delivery. This role leads both clinical pharmacology and nonclinical sciences, integrating PK/PD, exposure-response and dose-selection strategy with translational science and toxicology strategy across the pipeline. A successful candidate can effectively work cross-functionally and has a strong drug development track record of advancing programs from target discovery through IND/clinical stage.